首页> 外文期刊>Regulatory peptides. >Expression of IGF-I, IGF-I receptor and IGF binding proteins-1, -2, -3, -4 and -5 in human atherectomy specimens.
【24h】

Expression of IGF-I, IGF-I receptor and IGF binding proteins-1, -2, -3, -4 and -5 in human atherectomy specimens.

机译:在人斑斑切除术标本中IGF-1,IGF-1受体和IGF结合蛋白-1,-2,-3,-4和-5的表达。

获取原文
获取原文并翻译 | 示例
       

摘要

The molecular and cellular processes that induce rapid atherosclerotic plaque progression in patients with unstable angina and initiate restenosis following coronary interventional procedures are uncertain. We examined primary (de novo) and restenotic lesions retrieved at the time of directional coronary atherectomy for expression of insulin-like-growth factor-I (IGF-I). IGF-I receptor, and five IGF binding proteins (IGFBPs), IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, and IGFBP-5 in smooth muscle cells (SMCs) using colloidal gold immunocytochemistry. IGF-1, its receptor and binding proteins were not detected in SMCs of normal coronary arteries. IGF-I localized primarily in synthetic smooth muscle cells (sSMCs) in both de novo and restenotic plaques. IGF-I receptor localized on sSMCs and their processes and colocalized with IGF-I. Although morphometric analysis of IGF-I and IGF-I receptor immunoreactivity in sSMCs of de novo and restenotic lesions showed comparable levels of IGF-I (3.2 +/- 1.0 and 2.9 +/- 0.9,respectively). IGF-I receptor was significantly higher in de novo lesions as compared to restenotic lesions (10.7 +/- 2.5 and 4.2 +/- 1.3, P < 0.05, respectively). IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4 and IGFBP-5 localized in the cytoplasm of sSMCs and in the extracellular matrix. Quantitative reverse transcription polymerase chain reaction (QRT-PCR) performed on de novo atherectomy specimens identified mRNA for IGF-I, IGF-I receptor, IGFBP-1, IGFBP-2, IGFBP-4, IGFBP-5 levels and detected mRNA for IGFBP-3. The expression of IGF-I, IGF-I receptor, and IGFBPs in atherectomy plaques suggests that the development of coronary obstructive lesions may be a result of changes in the IGF system.
机译:不确定在不稳定型心绞痛患者中诱发动脉粥样硬化斑块快速发展并在冠状动脉介入治疗后引发再狭窄的分子和细胞过程。我们检查了在定向冠状动脉粥样斑块切除术时恢复的原发性(从头)和再狭窄病变中胰岛素样生长因子-I(IGF-I)的表达。使用胶体金免疫细胞化学技术检测平滑肌细胞(SMC)中的IGF-1受体和五个IGF结合蛋白(IGFBPs),IGFBP-1,IGFBP-2,IGFBP-3,IGFBP-4和IGFBP-5。在正常冠状动脉的SMC中未检测到IGF-1,其受体和结合蛋白。 IGF-1主要位于新生斑块和再狭窄斑块中的合成平滑肌细胞(sSMC)中。 IGF-I受体位于sSMC及其过程中,并与IGF-I共定位。尽管从头和再狭窄病变的sSMCs中IGF-I和IGF-I受体免疫反应性的形态分析表明,IGF-I的水平相当(分别为3.2 +/- 1.0和2.9 +/- 0.9)。与再狭窄病变相比,新生病变中的IGF-I受体明显更高(分别为10.7 +/- 2.5和4.2 +/- 1.3,P <0.05)。 IGFBP-1,IGFBP-2,IGFBP-3,IGFBP-4和IGFBP-5定位于sSMC的细胞质和细胞外基质中。在从头打旋切除术标本上进行的定量逆转录聚合酶链反应(QRT-PCR)确定了IGF-1,IGF-1受体,IGFBP-1,IGFBP-2,IGFBP-4,IGFBP-5水平的mRNA并检测了IGFBP的mRNA -3。斑块切除斑块中IGF-I,IGF-I受体和IGFBPs的表达表明,冠状动脉阻塞性病变的发展可能是IGF系统改变的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号